Lung cancer trials in France

In France 316 Also abroad 2733

316 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Lyon, Nantes, Paris, Villejuif
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
Phase 3Taking people
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Where
Créteil, Limoges, Marseille, Nantes, Paris, Pessac, Pierre-Bénite, Strasbourg
Age
18 years and over
People
734 worldwide
Run by
NovoCure GmbH
See details and how to joinNCT06216301
Phase 3Taking people
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Where
Brest, Bron, Clermont Ferrand Cedex1, Limoges, Paris, Paris Cedex 14, Rouen Cedex, Toulon Cedex 9, Toulouse, Valenciennes
Age
18 years and over
People
780 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00
Phase 3Taking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Avignon, Boulogne-Billancourt, Clermont Ferrand Cedex1, Dijon, Nice, Nimes Cedex 9, Quimper Cedex, Valenciennes
Age
18 years and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
No phaseTaking people
Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway
Where
Marseille
Age
45 years to 80 years
People
750
Run by
Assistance Publique Hopitaux De Marseille
See details and how to joinNCT06387017
No phaseTaking people
Evaluation of the Contribution of a DEMaterialized VIdeo-pedagogical SUpport in the Care Pathway of Lung Cancer Surgery Patients
Where
Marseille
Age
18 years and over
People
226
Run by
Assistance Publique Hopitaux De Marseille
See details and how to joinNCT06577844
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Where
Créteil, Grenoble Cedex 9, Lille, Marseille, Montpellier, Paris, Pierre-Bénite, Quimper Cedex, Villefranche Sur Saone Cedex, Villejuif
Age
18 years and over
People
530 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00
Phase 2Taking people
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
Where
Caen, Limoges, Pessac, Rennes, Toulon
Age
18 years and over
People
40 worldwide
Run by
Wayshine Biopharm, Inc.
See details and how to joinNCT06868485
Phase 1/2Taking people
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Where
Lyon, Marseille, Paris
Age
18 years and over
People
616 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT07020221
Phase 3Taking people
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Where
Boulogne-Billancourt, Grenoble, Saint-Herblain, Villejuif
Age
18 years and over
People
420 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07099898
Phase 3Taking people
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Where
Amiens, Caen, Chambéry, Marseille, Paris, Pau, VANDOEUVRE-LESNANCY
Age
18 years and over
People
675 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00
Phase 3Taking people
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Where
Boulogne-Billancourt, Lyon, Marseille, Saint-Herblain, Toulouse
Age
18 years and over
People
400 worldwide
Run by
AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00
Phase 3Taking people
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Where
Amiens, Boulogne-Billancourt, Caen Cedex 5, Créteil, Marseille, Montpellier, Orleans Cedex 2, Pessac, Saint-Herblain, Toulon Cedex 9, Vandoeuvre Les Nancy Cedex
Age
18 years and over
People
400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00
Phase 3Taking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Angers, Bordeaux, Caen Cedex 5, Dijon, Marseille, Paris, Saint-Herblain, Toulouse, Villefranche Sur Saone Cedex, Villejuif
Age
18 years and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
Phase 3Taking people
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Where
Boulogne-Billancourt, Caen Cedex 5, Créteil, Marseille, Montpellier, Pessac, Saint-Herblain, Valenciennes, Vandoeuvre Les Nancy
Age
18 years and over
People
310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00
Phase 3Taking people
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Where
Bron, Caen Cedex 5, Dijon, Grenoble Cedex 9, Lyon, Marseille, Paris, Quimper Cedex, Saint-Herblain, Toulouse, Villejuif
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00
Phase 1/2Taking people
A Study of DS-3939a in Participants With Solid Tumors
Where
Marseille, Montpellier, Paris, Rennes, Saint-Herblain, Suresnes, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
400 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07739966 · EU 2026-525218-75-00
Phase 1/2Taking people
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
Where
Lyon, Marseille, Villejuif Cedex
Age
18 years and over
People
55 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07843940 · EU 2026-525459-99-00
Phase 1Not yet taking people in France
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Where
Lyon, Saint-Herblain, Toulouse, Villejuif
Age
18 years and over
People
370 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00
Phase 3Not yet taking people in France
A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
Where
Amiens, Caen Cedex 5, Créteil, Limoges, Montpellier Cedex 5, Paris, Rennes Cedex 9, Villejuif
Age
18 years and over
People
95 worldwide
Run by
Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 · EU 2026-526300-67-00
No phaseTaking people
Analysis of Circulating Tumor Markers in Blood
Where
Montpellier
Age
18 years and over
People
992
Run by
Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT04025541
Phase 3Taking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Avignon, Bayonne, Bordeaux Cedex, Brest Cedex 2, Dijon, Le Mans Cedex 9, Lille, Marseille, Paris, Pierre-Bénite, Toulon, Toulouse, Vandoeuvre Les Nancy Cedex
Age
18 years and over
People
1,000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
Phase 3Taking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Caen, Lille, Lyon, Paris Cedex 13, Saint-Herblain Cedex, Tours, Villejuif
Age
18 years and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
Phase 1/2Taking people
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Where
Brest, Bron, Grenoble Cedex 9, Limoges
Age
18 years to 64 years
People
170 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07227597 · EU 2025-521032-11-00
Phase 2Taking people
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Where
Lyon, Paris
Age
18 years and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07486817 · EU 2025-523567-38-00